HK1050484A1 - Clonidine preparations - Google Patents

Clonidine preparations

Info

Publication number
HK1050484A1
HK1050484A1 HK03102665.7A HK03102665A HK1050484A1 HK 1050484 A1 HK1050484 A1 HK 1050484A1 HK 03102665 A HK03102665 A HK 03102665A HK 1050484 A1 HK1050484 A1 HK 1050484A1
Authority
HK
Hong Kong
Prior art keywords
clonidine
pain
per day
amount
preparations
Prior art date
Application number
HK03102665.7A
Other languages
English (en)
Inventor
Robert J Borgman
Original Assignee
Arcion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcion Therapeutics Inc filed Critical Arcion Therapeutics Inc
Publication of HK1050484A1 publication Critical patent/HK1050484A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Bending Of Plates, Rods, And Pipes (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
HK03102665.7A 1999-10-26 2003-04-11 Clonidine preparations HK1050484A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/427,367 US6147102A (en) 1999-10-26 1999-10-26 Clonidine preparations
PCT/US2000/028776 WO2001030345A1 (en) 1999-10-26 2000-10-18 Clonidine preparations

Publications (1)

Publication Number Publication Date
HK1050484A1 true HK1050484A1 (en) 2003-06-27

Family

ID=23694569

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03102665.7A HK1050484A1 (en) 1999-10-26 2003-04-11 Clonidine preparations

Country Status (13)

Country Link
US (2) US6147102A (xx)
EP (1) EP1248613B1 (xx)
JP (1) JP4901042B2 (xx)
CN (1) CN1148186C (xx)
AT (1) ATE499935T1 (xx)
AU (1) AU1211901A (xx)
CY (1) CY1111463T1 (xx)
DE (1) DE60045691D1 (xx)
DK (1) DK1248613T3 (xx)
ES (1) ES2359787T3 (xx)
HK (1) HK1050484A1 (xx)
PT (1) PT1248613E (xx)
WO (1) WO2001030345A1 (xx)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6559186B1 (en) 1990-02-26 2003-05-06 Arc 1, Inc. Compositions and methods of treatment of sympathetically maintained pain
US20030104041A1 (en) * 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US20050074487A1 (en) * 1999-12-16 2005-04-07 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US6544927B2 (en) 2001-04-28 2003-04-08 University Of Florida Use of α2-adrenergic receptor agonists and adrenergic inhibitors in reducing defoliation
US20030124174A1 (en) * 2001-10-25 2003-07-03 Endo Pharmaceuticals, Inc Method for treating non-neuropathic pain
US7687080B2 (en) * 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US7887842B2 (en) 2003-02-07 2011-02-15 Teikoku Pharma Usa, Inc. Methods of administering a dermatological agent to a subject
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US20050112183A1 (en) * 2003-11-25 2005-05-26 Galer Bradley S. Compositions and methods for treating neuropathic sensory loss
JP5044566B2 (ja) 2005-11-08 2012-10-10 アルション セラピューティクス， インコーポレイテッド 長さ依存性神経障害の処置
US8026266B2 (en) * 2005-11-08 2011-09-27 Arcion Therapeutics, Inc. Treatment of length dependent neuropathy
US8536445B2 (en) * 2006-06-02 2013-09-17 Emcore Solar Power, Inc. Inverted metamorphic multijunction solar cells
US20080102097A1 (en) * 2006-10-31 2008-05-01 Zanella John M Device and method for treating osteolysis using a drug depot to deliver an anti-inflammatory agent
CN101190183B (zh) * 2006-11-29 2010-05-12 上海医药工业研究院 一种盐酸可乐定多泡脂质体及其制备方法
US8470360B2 (en) 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
CN101536981B (zh) * 2008-03-19 2010-11-17 上海医药工业研究院 一种盐酸可乐定多囊脂质体及其制备方法
US9072727B2 (en) * 2008-04-18 2015-07-07 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of degenerative disc disease
US8420114B2 (en) * 2008-04-18 2013-04-16 Warsaw Orthopedic, Inc. Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
US9132085B2 (en) * 2008-04-18 2015-09-15 Warsaw Orthopedic, Inc. Compositions and methods for treating post-operative pain using clonidine and bupivacaine
US8883768B2 (en) * 2008-04-18 2014-11-11 Warsaw Orthopedic, Inc. Fluocinolone implants to protect against undesirable bone and cartilage destruction
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US20090263489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation
US9132119B2 (en) 2008-04-18 2015-09-15 Medtronic, Inc. Clonidine formulation in a polyorthoester carrier
US8722079B2 (en) * 2008-04-18 2014-05-13 Warsaw Orthopedic, Inc. Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine
US20090264489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation
US8629172B2 (en) 2008-04-18 2014-01-14 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising clonidine
US8956641B2 (en) * 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of inflammatory diseases
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US8557273B2 (en) * 2008-04-18 2013-10-15 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
US20090263451A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain
US8946277B2 (en) * 2008-04-18 2015-02-03 Warsaw Orthopedic, Inc. Clonidine formulations in a biodegradable polymer carrier
US9610243B2 (en) 2008-04-18 2017-04-04 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US20090264477A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc., An Indiana Corporation Beta adrenergic receptor agonists for treatment of pain and/or inflammation
US20100197694A1 (en) * 2008-08-01 2010-08-05 Gerald Horn Compositions and methods for treatment of diseases and conditions with increased vascular permeability
US20100202979A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
US20110003823A1 (en) * 2008-08-01 2011-01-06 Alpha Synergy Development, Inc. Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
JP5671459B2 (ja) * 2008-08-01 2015-02-18 アイ・セラピーズ・エル・エル・シー 血管収縮組成物および使用方法
US20100203165A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
AU2009296457A1 (en) * 2008-09-27 2010-04-01 Taraxos Inc. Topical formulations for treatment of neuropathy
US20100098746A1 (en) * 2008-10-20 2010-04-22 Warsaw Orthopedic, Inc. Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone
US8822546B2 (en) * 2008-12-01 2014-09-02 Medtronic, Inc. Flowable pharmaceutical depot
US20100228097A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Methods and compositions to diagnose pain
US20100239632A1 (en) * 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
US8617583B2 (en) * 2009-07-17 2013-12-31 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
US8231891B2 (en) * 2009-07-31 2012-07-31 Warsaw Orthopedic, Inc. Implantable drug depot for weight control
US20110097375A1 (en) 2009-10-26 2011-04-28 Warsaw Orthopedic, Inc. Formulation for preventing or reducing bleeding at a surgical site
EP2329849B1 (en) 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
BR112012024289A2 (pt) 2010-03-26 2017-07-18 Galderma Res & Dev "método para fornecer um tratamento seguro e efetivo do eritema e composição de gel tópica"
CA2792649A1 (en) 2010-03-26 2011-09-29 Michael Graeber Improved methods and compositions for safe and effective treatment of telangiectasia
CA2796280A1 (en) * 2010-04-15 2011-10-20 The Royal Institution For The Advancement Of Learning / Mcgill Universit Y Topical treatments for pain
CA2806062A1 (en) * 2010-07-19 2012-01-26 Arcion Therapeutics, Inc. Topical treatment of neuropathic pain and methods of diagnosis
WO2012012319A1 (en) 2010-07-19 2012-01-26 3M Innovative Properties Company Hand tool with replaceable knife cartridge
DK2444068T4 (en) 2010-10-21 2018-03-05 Galderma Sa Brimonide sub-composition
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
FR2977493B1 (fr) * 2011-07-05 2014-02-14 Galderma Res & Dev Nouvelle composition anesthesique stable pour la reduction des reactions cutanees
US9012486B2 (en) * 2011-11-14 2015-04-21 Alex Chervinsky Topical composition for pain relief
US20220142209A1 (en) * 2019-02-20 2022-05-12 Gregory Aharonian Methods and compositions for improving the taste of diet cola sodas and other beverages
WO2020222192A1 (en) 2019-05-01 2020-11-05 Clexio Biosciences Ltd. Methods of treating pruritus
MX2021012824A (es) 2019-05-01 2022-10-19 Clexio Biosciences Ltd Métodos para tratar el prurito.
GB202110420D0 (en) * 2021-07-20 2021-09-01 Rosemont Pharmaceuticals Ltd Liquid pharmaceutical composition of clonidine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801586A (en) * 1986-04-23 1989-01-31 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agents
IE60941B1 (en) * 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
US4808414A (en) * 1986-09-29 1989-02-28 Nelson Research & Development Co. Amide penetration enhancers for transdermal delivery of systemic agents
ATE75620T1 (de) * 1986-11-19 1992-05-15 Whitby Research Inc Penetrationsverbesserer fuer die transdermale verabreichung von systemisch wirksamen arzneimitteln.
US5462744A (en) * 1989-12-01 1995-10-31 Boehringer Ingelheim Kg Transdermal system for the administration of pharmacological compounds under pH-controlled conditions
US5070084A (en) * 1990-02-26 1991-12-03 Campbell James N Treatment of sympathetically maintained pain
US5447947A (en) * 1990-02-26 1995-09-05 Arc 1 Compositions and methods of treatment of sympathetically maintained pain
EP0516026A1 (en) * 1991-05-28 1992-12-02 Takeda Chemical Industries, Ltd. Hydrogel and method of producing same
JPH07500113A (ja) * 1991-10-16 1995-01-05 リチャードソン、ビックス、インコーポレーテッド 薬物の改善された局所送達用の高皮膚浸透系
US5605911A (en) * 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US6365178B1 (en) * 1996-09-06 2002-04-02 Watson Pharmaceuticals, Inc. Method of making pressure sensitive adhesive matrix patches for transdermal drug delivery using hydrophilic salts of drugs and hydrophobic pressure sensitive adhesive dispersions

Also Published As

Publication number Publication date
DK1248613T3 (da) 2011-05-16
EP1248613A1 (en) 2002-10-16
US6147102A (en) 2000-11-14
EP1248613A4 (en) 2006-03-22
CN1302608A (zh) 2001-07-11
JP4901042B2 (ja) 2012-03-21
CY1111463T1 (el) 2015-08-05
AU1211901A (en) 2001-05-08
DE60045691D1 (de) 2011-04-14
ATE499935T1 (de) 2011-03-15
EP1248613B1 (en) 2011-03-02
PT1248613E (pt) 2011-05-05
WO2001030345A1 (en) 2001-05-03
CN1148186C (zh) 2004-05-05
US6534048B1 (en) 2003-03-18
ES2359787T3 (es) 2011-05-26
JP2003512427A (ja) 2003-04-02

Similar Documents

Publication Publication Date Title
HK1050484A1 (en) Clonidine preparations
CA2033499A1 (en) Method for percutaneous delivery of ibuprofen using hydroalcoholic gel
CA2274074A1 (en) Novel compounds with analgesic effect
WO2000027381A3 (en) Topical application of muscarinic agents such as neostigmine for treatment of acne and other inflammatory conditions
CA2214097A1 (en) Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx
NZ504076A (en) A topical formulation which induces a minimal systemic effect when applied to the skin, the topical formulation comprising an immunosuppressive macrolide selected from sirolimus, FK506 and SDZ ASM 981 and a permeation modulator for the treatment of a dermatological condition
WO1996003151A3 (en) Intracellular expression of carboxypeptidase g2 in enzyme prodrug therapy
IS4146A (is) Lyfjablanda til að gefa dýrum um munn sem inniheldur prótonupumpublokkara
CA2404810A1 (en) Topical composition having undifferentiated plant seed cells and method for using same
NO954878L (no) Pyrrolderivater
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
CA2284774A1 (en) Theobromine antitussive compositions
EP1310256A3 (en) Use of prostaglandin A or its derivatives for the treatment of psoriasis
AU4830097A (en) Use of an extract of Cimicifuga
PH31320A (en) Fenbendazole formulations.
ES2137125A1 (es) La utilizacion de la sal de zinc del acido glicirretico en preparados contra el acne y las composiciones que contienen dicha sal.
CA2417935A1 (en) Anti-inflammatory medicament
AU2420001A (en) Methods and compositions for the treatment of pain
EP0535237A4 (en) Composition for relieving skin irritation and external preparation for percutaneous adminstration containing the same
AU3946197A (en) Cosmetic, dermatological and pharmaceutical use of a terminalia catappa extract
ATE254851T1 (de) Iod-herstellungszusammensetzung
AU6241096A (en) A cosmetic antimycotic composition for skin applications and pharmaceutical composition for the treatment of tumorous cells, bladder or nerve disorders
YU13599A (sh) Primena farmaceutske kompozicije za dobijanje leka u obliku gela
ZA988820B (en) Use of delta-aminolaevulinic acid for the preparation of a topical medicament for the integral diagnosis and/or therapy of tumours in hollow organs
ES2156763A1 (es) Formulacion estables de solucion de apomorfina.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20171018